Fabry Disease Treatment Market, Size, Share 2021-2028
Added: (Tue Nov 23 2021)
Pressbox (Press Release) -
Market Overview
The global Fabry Disease Treatment Market size was valued US$ XX billion in 2020 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).
Fabry disease also called as Anderson-Fabry disease and alpha-galactosidase-A deficiency is an X-linked, hereditary, lysosomal storage disease caused due to paucity of an enzyme α galactosidase A (an enzyme required to metabolize lipids, fat-like substances that include oils, waxes, and fatty acids).
Download free sample: https://www.datamintelligence.com/download-sample/fabry-disease-treatment-market
Market Dynamics
The global fabry disease treatment market growth is driven by the expanding base of patients suffering from fabry disease coupled with increased adoption of novel therapies such as chaperone treatment has helped the market gain momentum. Besides this, extensive R&D activities and potential approval of promising pipeline products including substrate reduction therapies and enzyme replacement therapies are projected to drive the growth of the over the forecast period.
The presence of robust medication pipeline indicated for treatment of fabry disease is expected to drive the growth in the forecast period
The presence of robust medication pipeline indicated for treatment of fabry disease is also expected to be a major factor fueling growth of global fabry disease treatment market over the forecast period.
In recent past, various regulatory bodies of key regions have approved novel medications for treatment of fabry disease. Approval and launch of such novel medications is expected to significantly support global fabry disease treatment market growth over the forecast period.
For instance, in August 2018, Amicus Therapeutics, Inc., received the U.S. Food and Drug Administration (FDA) approval for its drug Galafold (migalastat). It is the first oral medication indicated for the treatment of adults with Fabry disease.
Furthermore, key players in the market are majorly investing in development of novel therapies for Fabry disease treatment, such strategic funding’s by various players is expected to drastically fuel global fabry disease treatment market growth over the forecast period.
For instance, in February 2018, AvroBio Inc., closed US$ 60 million financing to support the phase 2 study of its novel gene therapy, AVR-RD-01 underdevelopment for the treatment of Fabry disease. Considering these factors will drive the growth of the market in the forecast period.
Lack of a curative solution for Fabry disease treatment are projected, expected to drive the market growth
Patients suffering from Fabry disease commonly experience stroke, extreme pain, early heart disorder, compromised kidney function often leading to full kidney failure, and disabling gastrointestinal symptoms. Due to this lack of a curative solution for Fabry disease treatment options aims to manage complications associated with disease progression and giving symptomatic relief. Many of times, various patients remain undiagnosed due to moderate symptoms. Considering these factors, the global fabry disease market is projected to grow at a significate rate in the forecast period.
Low diagnostic rate due to unavailability of such diagnostic procedures and trained professionals is likely to hinder the market growth
However, fabry disease is a very rare disease affecting around 1 individual in 50,000 (according to the National Fabry Disease Foundation), the diagnosis of Fabry disease is confirmed by demonstrating an enzyme deficiency in males and by identifying the specific GLA gene mutation in males and females. Hence, low diagnostic rate due to unavailability of such diagnostic procedures and trained professionals in emerging economies are expected to be major factor restraining global fabry disease treatment market growth.
COVID-19 Impact Analysis
Coronavirus Disease-19 (COVID-19), caused by the SARS-CoV-2 virus was labeled as a global pandemic and patients with fabry disease can be considered at high risk of developing severe complications. The impact of COVID-19 on patients with fabry disease receiving enzyme replacement therapy is still unknown. Many patients who receive treatment in the hospital experienced infusion disruptions due to fear of infection. Effects of temporary treatment interruption was described in more detail in other lysosomal storage diseases, but the recommencement of therapy does not fully reverse clinical decline due to the temporary discontinuation. When possible, home-therapy seems to be the most efficient way to maintain enzyme replacement therapy access during pandemic. These factors will drive the growth of the market in the forecast period.
Segment Analysis:
– By Drugs
• Approved Drugs *
• Agalsidase Beta (Fabrazyme/Replagal)
• Migalastat (Galafold)
• Pipeline Drugs
– By Treatment
• Enzyme Replacement Therapy (ERT) *
• Chaperone Treatment
• Substrate Reduction Therapy (SRT)
• Others
Geographical Analysis
North America region holds the largest market share global Fabry Disease Treatment Market
North America region is dominating the global Fabry Disease Treatment Market accounted for the largest market share in 2020. Higher adoption of novel therapies, better healthcare facilities, and favorable reimbursement policies are playing a vital role in the growth of the market in the region. Coverage of expensive medications such as Fabrazyme by health insurance programs and favorable governmental healthcare policies are also prompting drug companies to increase R&D investments in the field of rare diseases.
Competitive Landscape
The Fabry Disease Treatment Market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Amgen Inc., Amicus Therapeutics, Inc., Bristol-Myers Squibb Company, GlaxoSmithKline, iBio, Inc., Neuraltus Pharmaceuticals, Inc., Novartis AG, Pfizer Inc., AVROBIO, Inc., Idorsia Pharmaceuticals Ltd, Protalix, Sanofi, Shire, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the Fabry Disease Treatment Market globally.
Sanofi S.A
Overview: Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Specialty Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations.
Product Portfolio: The Company’s portfolio comprised of drugs, generic medicines, food supplement, and cosmetics.
View Full Report: https://www.datamintelligence.com/research-report/fabry-disease-treatment-market
Enquiry Before Buying: https://www.datamintelligence.com/enquiry/fabry-disease-treatment-market
About Us
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year, we have secured more than 100 unique customers from established organizations all over the world.
For more information:
Sai Kiran
Sales Manager at DataM Intelligence
Email: info@datamintelligence.com
Tel: +1 877 441 4866
Website: www.datamintelligence.com